Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus.